The present application is directed to compounds of Formula (I)-(VIII): ##STR00001## compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics.

The present application is directed to compounds of Formula (I)-(VIII): ##STR00001## compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics.

A method for producing a fluorine-containing compound represented by General formula (1), wherein X represents a halogen atom or an alkoxy group, R.sup.1 represents a hydrogen atom or a linear, branched, or cyclic alkyl group having 1 to 10 carbon atoms, R.sup.f1 and R.sup.f2 are each independently a fluorinated alkoxy group, and n represents an integer of 0 or more. ##STR00001##

A method for producing a fluorine-containing compound represented by General formula (1), wherein X represents a halogen atom or an alkoxy group, R.sup.1 represents a hydrogen atom or a linear, branched, or cyclic alkyl group having 1 to 10 carbon atoms, R.sup.f1 and R.sup.f2 are each independently a fluorinated alkoxy group, and n represents an integer of 0 or more. ##STR00001##

Disclosed herein are compositions and methods for preparation and delivery of protein therapeutics, and more particularly reversible linkers and use thereof.

Disclosed herein are compositions and methods for preparation and delivery of protein therapeutics, and more particularly reversible linkers and use thereof.

Disclosed are nitrosourea and other compounds, pharmaceutical composition, and methods of treating cancers that are MGMT deficient regardless of their MMR status and particularly compounds, pharmaceutical compositions, and methods of treating cancers that are both MGMT and MMR deficient.

Disclosed are nitrosourea and other compounds, pharmaceutical composition, and methods of treating cancers that are MGMT deficient regardless of their MMR status and particularly compounds, pharmaceutical compositions, and methods of treating cancers that are both MGMT and MMR deficient.

Methods of analyzing a drug polypeptide conjugate using tandem mass spectrometry involving dual tandem mass tags (TMTs) are described. Provided herein is an integrated method using TMTs to obtain three analytical measurements, termed “triple play”, which enables identification of the drug occupancy, normalization between multiple samples and triggering of additional MS/MS to identify and localize conjugation site(s) of the payload. Also described is a method of multiplexing conjugation reactions in a single run with TMT labeling for enhanced throughput capability, while maintaining the same sensitivity with current mass spectrometry instrumentation.

Compounds and methods of treating HIV-1 in a human infected with HIV-1 or preventing HIV-1 infection in a human susceptible to infection with HIV-1 are provided. The compounds are of formula (I), (II), and (IA), wherein R.sup.1-R.sup.7, X, X′, Y, Y′, Z, and n are defined herein, and the methods comprises administering therapeutically effective amounts of these compounds to the human.

##STR00001##